Indwelling Intrauterine Foley Balloon Catheter for Intraoperative and Postoperative Bleeding in Cesarean Scar Pregnancy

Lü, Yanming; Guo, Yaru; Zhou, Mengya; Wang, Yue

doi:10.1016/j.jmig.2019.02.024

Cited by 12 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 358 articles were identified; 122 were assessed with respect to their eligibility for inclusion and 44 studies were included in the systematic review (Table 1, Figure 1). 9,10,21‐61 These studies included 3598 women with a prior CSP; of these, information on subsequent pregnancy was available for 592 women.…”

Section: Resultsmentioning

confidence: 99%

Reproductive outcome after cesarean scar pregnancy: A systematic review and meta‐analysis

Morlando

Buca

Timor‐Tritsch

et al. 2020

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction To evaluate subsequent reproductive among women with a prior cesarean scar pregnancy (CSP). Material and methods MEDLINE, Embase and ClinicalTrials.gov databases were searched. Inclusion criteria were women with a prior CSP, defined as the gestational sac or trophoblast within the dehiscence/niche of the previous cesarean section scar or implanted on top of it. The primary outcome was the recurrence of CSP; secondary outcomes were the chance of achieving a pregnancy after CSP, miscarriage, preterm birth, uterine rupture and the occurrence of placenta accreta spectrum disorders. Subgroup analysis according to the management of CSP (surgical vs non‐surgical) was also performed. Random effect meta‐analyses of proportions were used to analyze the data. Results Forty‐four studies (3598 women with CSP) were included. CSP recurred in 17.6% of women. Miscarriage, preterm birth and placenta accreta spectrum disorders complicated 19.1% (65/341), 10.3% (25/243) and 4.0% of pregnancies, and 67.0% were uncomplicated. When stratifying the analysis according to the type of management, CSP recurred in 21% of women undergoing surgical and in 15.2% of those undergoing non‐surgical management. Placenta accreta spectrum disorders complicated 4.0% and 12.0% of cases, respectively. Conclusions Women with a prior CSP are at high risk of recurrence, miscarriage, preterm birth and placenta accreta spectrum. There is still insufficient evidence to elucidate whether the type of management adopted (surgical vs non‐surgical) can impact reproductive outcome after CSP. Further large, prospective studies sharing an objective protocol of prenatal management and long‐term follow up are needed to establish the optimal management of CSP and to elucidate whether it may affect its risk of recurrence and pregnancy outcome in subsequent gestations.

show abstract

Section: Resultsmentioning

confidence: 99%

Reproductive outcome after cesarean scar pregnancy: A systematic review and meta‐analysis

Morlando

Buca

Timor‐Tritsch

et al. 2020

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…Balloon occlusion is a temporary means of mechanical occlusion of the blood supply, as the balloon is intravascularly precisely transported under DSA guidance. This method helps to reduce intraoperative bleeding [ 22 ]. At present, abdominal aortic balloon occlusion in obstetric and gynaecologic surgeries blocks most of the pelvic blood supply, thereby effectively controlling bleeding in the abdominal aortic plane [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of prophylactic abdominal aortic balloon occlusion for patients with type III caesarean scar pregnancy: a prospective cohort study

Wu,

Guo,

et al. 2023

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background Caesarean scar pregnancy (CSP) is a special type of ectopic pregnancy with a high risk of massive haemorrhage. Few studies have focused on the efficacy of prophylactic abdominal aortic balloon occlusion as a minimally invasive method in caesarean section. This study aimed to evaluate the effectiveness and safety of prophylactic abdominal aortic balloon occlusion for patients with type III CSP. Methods This was a prospective cohort study. Patients with type III CSP in the First Affiliated Hospital of Zhengzhou University from January 2020 to June 2022 were enrolled. Eligible patients received prophylactic abdominal aortic balloon occlusion (defined as the AABO group) or uterine artery embolization (defined as the UAE group) before laparoscopic surgery. Clinical outcomes included intraoperative blood loss, body surface radiation dose, hospitalization expenses, and time to serum β-hCG normalization, and safety were also assessed. Results A total of 68 patients met the criteria for the study, of whom 34 patients were in the AABO group and 34 patients were in the UAE group. The median intraoperative blood loss in the AABO and UAE groups was 17.5 (interquartile ranges [IQR]: 10, 45) and 10 (IQR: 6.25, 20) mL, respectively (P = 0.264). The body surface radiation dose of the AABO group was much lower than that of the UAE group (5.22 ± 0.44 vs. 1441.85 ± 11.59 mGy, P < 0.001). The AABO group also had lower hospitalization expenses than the UAE group (2.42 ± 0.51 vs. 3.42 ± 0.85 *10^5 yuan, P < 0.001). The average time to serum β-hCG normalization in the AABO group was 28.9 ± 3.21 d, which was similar to that in the UAE group (30.3 ± 3.72 d, P = 0.099). In addition, the incidence of adverse events in the AABO group was lower than that in the UAE group (5.9% vs. 58.8%, P < 0.001). Conclusion Prophylactic AABO was equally as effective as UAE in patients with type III CSP but was safer than UAE during and after the operation.

show abstract

“…Проведений аналіз публічної інформації за 10 років в інформаційному просторі Pubmed показав, що використання балонної тампонади присвячено біля 720 наукових публікацій в основній мірі в акушерстві, але щодо використання в гінекології для лікування АМК, даний метод знаходить дуже рідке застосування. Багато публікації присвячено балонній терм абляції ендометрія з застосуванням балону TermaChoice, (Cavaterm) при патології ендометрія, або як противоспайкові бар'єри після резекції або абляції ендометрія для профілактики синдрому Ашермана, але для зупинки гострих АМК даний метод не використовувався [7][8][9][10][11][12].…”

Section: за данимиunclassified

Балонна Гідротампонада Матки При Лікуванні Аномальних Маткових Кровотеч

Khaskhachykh¹,

Потапов²

2022

GoS

View full text Add to dashboard Cite

У статті представлений огляд нашого досвіду застосування внутрішньоматкової тампонади балонними катетерами типу Бакрі оригінальної конструкції при тяжких аномальних маткових кровотечах (ТАМК) у жінок. Це звіт про серію випадків у 33 пацієнток, у яких використовували внутрішньоматкову балонну тампонаду. Ми ідентифікували цих пацієнток за класифікацією PALM-COEN і застосовували балонну тампонаду матки на першому етапі комплексної терапії для зупинки маткової кровотечі з подальшим з’ясуванням причини і патогенетичного лікування. При установці катетеру зупинити маткову кровотечу вдалося у 100% випадків. Висновком проведеного дослідження стало те, що балонна гідротампонада матки є простим, безпечним і досить ефективним допоміжним засобом на першому етапі лікування АМК спричиненими різноманітними причинами, особливо, при їх рецидивах, що допомагає зменшити об’єм кровотечі, покращити ефективність діагностики і терапії. Подальше дослідження методу балонної гідротампонади матки для першого етапу лікування АМК може покращити його ефективність і зменшити кількість оперативних втручань.

show abstract

Indwelling Intrauterine Foley Balloon Catheter for Intraoperative and Postoperative Bleeding in Cesarean Scar Pregnancy

Cited by 12 publications

References 22 publications

Reproductive outcome after cesarean scar pregnancy: A systematic review and meta‐analysis

Reproductive outcome after cesarean scar pregnancy: A systematic review and meta‐analysis

Effectiveness and safety of prophylactic abdominal aortic balloon occlusion for patients with type III caesarean scar pregnancy: a prospective cohort study

Балонна Гідротампонада Матки При Лікуванні Аномальних Маткових Кровотеч

Contact Info

Product

Resources

About